top of page
The Professional Network for Healthcare Experts
Atavistik Bio and Roche sign allosteric drug discovery collaboration worth up to $1.9bn
The collaboration gives Roche access to Atavistik Bio's AMPS platform to discover allosteric small molecules across cardiovascular, renal and metabolic disease targets.
nuaxia
Sep 281 min read
Zealand Pharma begins Phase 3 ZUPREME programme for petrelintide in obesity
Zealand Pharma and Roche have started the global Phase 3 ZUPREME programme evaluating once-weekly petrelintide as a treatment for people with overweight or obesity.
nuaxia
Sep 242 min read
bottom of page